Great Novel Therapeutics Biotech & Medicals Common Stock

The latest common stock for 7427.TWO is $540M as of June 2026. That compares with $440M in the prior-year period — up 23.8% year over year. Investors often review this figure alongside Great Novel Therapeutics Biotech & Medicals's historical trend and sector peers before judging valuation or financial health.

Over the past year, 7427.TWO's common stock moved from $440M to $540M — a 23.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Great Novel Therapeutics Biotech & Medicals's operating scale or balance-sheet position.

A common stock figure of $540M for 7427.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 7427.TWO's common stock ($540M), review year-over-year change from $440M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Great Novel Therapeutics Biotech & Medicals's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.